Valuation: EnteroMedics Inc

Market Cap 13.41M 11.91M 11.12M 10.13M 19.11M 1.29B 19.29M 135M 52.13M 659M 50.33M 49.24M 2.11B P/E 2026 *
-3.5x
P/E 2027 * -2.39x
Enterprise Value 13.41M 11.91M 11.12M 10.13M 19.11M 1.29B 19.29M 135M 52.13M 659M 50.33M 49.24M 2.11B EV / Sales 2026 *
122x
EV / Sales 2027 * 67x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 110K 97.29K 90.81K 82.77K 156K 10.53M 158K 1.1M 426K 5.38M 411K 402K 17.27M 200K 178K 166K 151K 285K 19.23M 288K 2.01M 778K 9.83M 751K 735K 31.54M
Net income -3.8M -3.38M -3.15M -2.87M -5.42M -365M -5.47M -38.14M -14.78M -187M -14.27M -13.96M -599M -7.85M -6.97M -6.51M -5.93M -11.18M -754M -11.29M -78.74M -30.51M -386M -29.46M -28.82M -1.24B
Net Debt - -
Logo EnteroMedics Inc
ReShape Lifesciences Inc. is a weight-loss and metabolic health-solutions company. The Company offers an integrated portfolio of products and services that manage and treat obesity and metabolic disease. Its Lap-Band System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures, such as gastric bypass or sleeve gastrectomy. The investigational Diabetes Bloc-Stim Neuromodulation (DBSN) system utilizes a vagus nerve block and stimulation technology platform for the treatment of type II diabetes and metabolic disorders. The Obalon balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. Its ReShape Calibration tubes are multifunctional devices compared to reusable bougies and disposable gastric tubes. Its Lap-Band 2.0, like the original Lap-Band System, is designed to provide minimally invasive long-term treatment of severe obesity.
Employees
-
Sector
-